Literature DB >> 24762402

Length polymorphism in heme oxygenase-1 and risk of CKD among patients with coronary artery disease.

Yu-Hsin Chen1, Ko-Lin Kuo2, Szu-Chun Hung2, Chih-Cheng Hsu3, Ying-Hwa Chen4, Der-Cherng Tarng5.   

Abstract

The length polymorphism of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with cardiovascular events and mortality in high-risk populations. Experimental data suggest that heme oxygenase-1 protects against kidney disease. However, the association between this polymorphism and long-term risk of CKD in high-risk patients is unknown. We analyzed the allelic frequencies of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter in 386 patients with coronary artery disease recruited from January 1999 to July 2001 and followed until August 31, 2012. The S allele represents short repeats (<27), and the L allele represents long repeats (≥27). The primary renal end points consisted of sustained serum creatinine doubling and/or ESRD requiring long-term RRT. The secondary end points were major adverse cardiovascular events and mortality. At the end of study, the adjusted hazard ratios (95% confidence intervals) for each L allele in the additive model were 1.99 (1.27 to 3.14; P=0.003) for the renal end points, 1.70 (1.27 to 2.27; P<0.001) for major adverse cardiovascular events, and 1.36 (1.04 to 1.79; P=0.03) for mortality. With cardiac events as time-dependent covariates, the adjusted hazard ratio for each L allele in the additive model was 1.91 (1.20 to 3.06; P=0.01) for the renal end points. In conclusion, a greater number of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with higher risk for CKD, cardiovascular events, and mortality among patients with coronary artery disease.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  CKD; coronary artery disease; guanosine thymidine dinucleotide; heme oxygenase-1; mortality; polymorphism

Mesh:

Substances:

Year:  2014        PMID: 24762402      PMCID: PMC4214532          DOI: 10.1681/ASN.2013111205

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  40 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty.

Authors:  M Exner; M Schillinger; E Minar; W Mlekusch; G Schlerka; M Haumer; C Mannhalter; O Wagner
Journal:  J Endovasc Ther       Date:  2001-10       Impact factor: 3.487

Review 3.  Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression.

Authors:  Anupam Agarwal; Harry S Nick
Journal:  J Am Soc Nephrol       Date:  2000-05       Impact factor: 10.121

4.  Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  S H Juan; T S Lee; K W Tseng; J Y Liou; S K Shyue; K K Wu; L Y Chau
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

5.  Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients.

Authors:  Ying-Hwa Chen; Shing-Jong Lin; Ming-Wei Lin; Hui-Ling Tsai; San-San Kuo; Jaw-Wen Chen; Min-Ji Charng; Tao-Cheng Wu; Lung-Ching Chen; Yu-An Ding; Wen-Harn Pan; Yuh-Shan Jou; Lee-Young Chau
Journal:  Hum Genet       Date:  2002-06-19       Impact factor: 4.132

6.  Protective effect of heme oxygenase-1 on hepatic ischemia-reperfusion injury through inhibition of platelet adhesion to the sinusoids.

Authors:  Takafumi Tamura; Tadashi Kondo; Koichi Ogawa; Kiyoshi Fukunaga; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2013-04       Impact factor: 4.029

7.  Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis.

Authors:  Jeong-Hae Kie; Matthias H Kapturczak; Amie Traylor; Anupam Agarwal; Nathalie Hill-Kapturczak
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

8.  Length polymorphism in heme oxygenase-1 and cardiovascular events and mortality in hemodialysis patients.

Authors:  Yu-Hsin Chen; Szu-Chun Hung; Der-Cherng Tarng
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

9.  The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality.

Authors:  Ho Jun Chin; Hyun Jin Cho; Tae Woo Lee; Ki Young Na; Hyung Jin Yoon; Dong-Wan Chae; Suhnggwon Kim; Un Sil Jeon; Jun-Young Do; Jong-Won Park; Kyung-Woo Yoon; Young-Tai Shin; Kang Wook Lee; Ki-Ryang Na; Dae Ryong Cha; Young Sun Kang
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

10.  Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study).

Authors:  Nicola Lüblinghoff; Karl Winkler; Bernhard R Winkelmann; Ursula Seelhorst; Britta Wellnitz; Bernhard O Boehm; Winfried März; Michael M Hoffmann
Journal:  BMC Med Genet       Date:  2009-04-23       Impact factor: 2.103

View more
  15 in total

Review 1.  Heme Oxygenase-1 in Kidney Health and Disease.

Authors:  Jeremie M Lever; Ravindra Boddu; James F George; Anupam Agarwal
Journal:  Antioxid Redox Signal       Date:  2016-05-26       Impact factor: 8.401

Review 2.  Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  Transl Res       Date:  2015-06-23       Impact factor: 7.012

3.  Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.

Authors:  Santosh L Saraf; Xu Zhang; Binal Shah; Tamir Kanias; Krishnamurthy P Gudehithlu; Rick Kittles; Roberto F Machado; Jose A L Arruda; Mark T Gladwin; Ashok K Singh; Victor R Gordeuk
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

Review 4.  Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.

Authors:  Jeffrey B Kopp; Cheryl A Winkler
Journal:  Semin Nephrol       Date:  2018-07       Impact factor: 5.299

5.  Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery.

Authors:  David E Leaf; Simon C Body; Jochen D Muehlschlegel; Gearoid M McMahon; Peter Lichtner; Charles D Collard; Stanton K Shernan; Amanda A Fox; Sushrut S Waikar
Journal:  J Am Soc Nephrol       Date:  2016-06-02       Impact factor: 10.121

Review 6.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

Review 7.  Heme Oxygenase 1 as a Therapeutic Target in Acute Kidney Injury.

Authors:  Subhashini Bolisetty; Abolfazl Zarjou; Anupam Agarwal
Journal:  Am J Kidney Dis       Date:  2017-01-27       Impact factor: 8.860

8.  Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.

Authors:  Travis D Hull; Anupam Agarwal
Journal:  Diabetes       Date:  2014-08       Impact factor: 9.461

9.  Specific expression of heme oxygenase-1 by myeloid cells modulates renal ischemia-reperfusion injury.

Authors:  Maxime Rossi; Antoine Thierry; Sandrine Delbauve; Nicolas Preyat; Miguel P Soares; Thierry Roumeguère; Oberdan Leo; Véronique Flamand; Alain Le Moine; Jean-Michel Hougardy
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

10.  Polymorphisms in the heme oxygenase-1 and bone morphogenetic protein receptor type 1b genes and estimated glomerular filtration rate in Brazilian sickle cell anemia patients.

Authors:  Okeke Chinedu; Wouitchékpo Vincent Tonassé; Dulcinéia Martins Albuquerque; Igor de Farias Domingos; Aderson da Silva Araújo; Marcos André Cavalcanti Bezerra; Maria de Fátima Sonati; Magnun Nueldo Nunes Dos Santos
Journal:  Hematol Transfus Cell Ther       Date:  2020-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.